Originally published September 16, 2020

Targeted immunotherapy has revolutionized the treatment of non–small cell lung cancer (NSCLC). Specifically, the U.S. Food and Drug Administration approvals of nivolumab, pembrolizumab, and atezolizumab have improved outcomes in the metastatic NSCLC setting, and work to improve care further is ongoing.

One of the researchers working within the lung cancer space is Jyoti Malhotra, MD, MPH, a medical oncologist at Rutgers Cancer Institute of New Jersey and assistant professor of medicine at Robert Wood Johnson Medical School.

Dr. Malhotra, who previously received a Young Investigator Award (YIA) funded by Conquer Cancer, the ASCO Foundation, recently published data from a phase I multicenter trial that tested PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced unresectable NSCLC. The trial found that administering immunotherapy concurrently with chemotherapy and radiation is safe and tolerable.

Read more in ASCO Daily News.